Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBT-401-1S for moderate to severe ulcerative colitis
2020-003556-33Phase 2Completed
- Sponsor
- Bridge Biotherapeutics
- Start
- Feb 2021
- Modality
- Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing BBT-401-1S with Placebo (2 arms). Primary endpoint: Clinical response rate at Day 57. Started Feb 2021; status: completed.
02
Drugs
BBT-401
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2020-003556-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003556-33.